Quarterly review – changes to Prime Funds, our fund recommendations

If there’s one trend that equity funds don’t seem to be shaking off soon, it is the performance divergence. Over the past few review cycles, we have been highlighting how up-and-coming funds have soared well past the earlier steady performers. Taking stock of the underperformers, the nature of market movements, and returns we have made some key changes to our equity funds in this review cycle. 

changes to Prime Funds

On the debt side, we have been very active with our changes over the past year to build recommendations that can cover any interest rate changes that unfold. Therefore, we have held back from changes in debt funds this review cycle.
Here are the changes we have made to Prime Funds in this March 2022 quarter review cycle.

About Prime Funds

New to PrimeInvestor? This is what you need to know about Prime Funds: 

Prime Funds is our list of best mutual funds across the equity, debt, and hybrid categories. We use Prime Ratings, our fund ratings, as a first filter. We then apply qualitative analysis to arrive at our fund recommendations. Prime Funds is an enduring list of funds that you can use at any time and you will find a fund that meets any goal you’re looking to meet. 

Different categories: Prime Funds are separated into buckets, based on risk level in equity & hybrid funds and timeframe in debt funds. Each of these draws from different SEBI-defined categories. We have classified them in a more user-friendly way than using the several dozens of SEBI categories. We do not go only by Prime Ratings but look at other factors as well to narrow the list and make the choices easy for you. 

Different styles: In Prime Funds, we’ve aimed at providing funds that follow different strategies for you to mix styles and diversify your portfolio with ease. The ‘Why this fund’ for each Prime Fund will brief its strategy, why we picked it, and how to use it in your portfolio.

Direct plans: We have specifically given the direct plans in Prime Funds. If you wish to know whether it is ok for you to use the regular plan of the fund, check our MF Review Tool (not our Ratings). If the review specifies ‘buy through direct,’ it means that the expense ratio differential is high under the regular plan for that fund. You will be better off using the direct plan in such cases. You can also check the expense ratio differential using our expense ratio tool.

Quarterly review: Our aim in reviewing the Prime Funds list every quarter is to ensure that we don’t miss any good opportunities that are coming up and we are not holding on to funds that are slipping. When we remove funds from the Prime Funds list, we tell you exactly what to do if you have invested in these funds. Funds we remove do not immediately call for a sell – it is just that they have slipped in performance marginally or there are better alternatives now. Unless our review tool says such funds are a ‘sell’, you can hold them (refer to our article on when to sell funds)

Using Prime Funds: You don’t need to hold every Prime Fund nor add any new fund we introduce to the list. Unless it fits your overall portfolio/strategy, or there is something lacking, there is little need for you to go on adding funds. Our idea of covering them in detail through some of our weekly calls is to let you know the strategy, style, and suitability in different portfolios. It is not a specific call to buy right away, unless we mention that it is a ‘tactical’ or ‘timing’ call.

Equity funds

The Nifty 50 and Sensex hit their peak in October 2021 while the mid-cap and small-cap indices hit a couple of months later. Questions over higher interest rates and the inflation trajectory had already begun to draw FPIs away from our markets. And from February, the war-driven chaos sent commodity prices spiralling and equity markets correcting. FPIs selling rapidly rose, though domestic institutional buying provided some support. 

Though markets appear to have calmed somewhat in the past week or so, the cloud of higher inflation across the board, supply chain snags, and the impact on consumption and industry still hang – both in our own markets and globally. The same holds with interest rates.

We have refrained so far from making very drastic changes in equity funds in Prime Funds. One, we had been sceptical about the outsized fund performers in a bull run because we were unsure about their ability to sustain returns if markets corrected. Two, funds we picked have sound strategies driven by fundamentals, which take time to play out. We did not want to penalise funds for placing stock quality above returns. 

And barring a few, our equity fund recommendations have panned out well; funds have beaten their benchmarks, or many that were underperformers have since rebounded. 

Still, a few factors are making us redraw our approach to fund recommendations:

  •  We were hesitant to add funds that started performing post 2020. We were not sure whether these bull market funds would sustain performance. But the past 6 months have offered a window into understanding how these funds managed volatility and correction. Those that won our confidence on this front have been added to our list now.
  • Similarly, this volatility together with the run-up over the past two years helped gauge whether earlier strong performers but current underperformers are holding up. Funds that were unable to pick up even over this period mean opportunity loss. We therefore decided to remove such funds from our list. 
  • We also took a relook at our philosophy of being very long term with funds that have sound portfolio fundamentals. We realised that quicker churns in sector preferences and a rapid rise in stock prices make it harder to rely only on long-term, fundamentally-driven, buy-and-hold funds. Funds that are more tactical by nature, or which quickly churn portfolios, or are momentum-driven are better-placed to deliver when the market does.

Therefore, changes we have made this quarter in Prime Funds keeps the above points in mind.

Equity – Moderate

Kotak Flexicap is a fund we have been watching for a performance improvement – and discussing in our reviews! – for about three quarters now. As we noted in our review last quarter, the fund did seem to be recovering, especially with short-term returns improving against the Nifty 500 and the Nifty 200 (since it’s predominantly a large-cap fund). 

However, the fund has since lost that edge. Its lag compared to the Nifty 500 TRI remains wide at 5-7 percentage points, and this gap shows no signs of narrowing on a sustained basis. Therefore, we are removing Kotak Flexicap from this Prime Funds category. Given its long-term performance, strategy, and attempts to improve, you can hold all investments made in this fund.

If you have SIPs in the fund, stop them. Continue to hold all investments made so far in the fund. For those who hold the fund as part of your Prime Portfolio, please wait for our alert. We will give you the necessary changes to make.

We are adding PGIM Flexicap to this category. This fund is the most aggressive in this set, both in terms of market-cap allocation and strategy. The fund follows a quality, bottom-up approach. It can shift its portfolio rapidly and often sees high churn. This opportunity-driven strategy has helped the fund score exceptionally well on the upside. PGIM Flexicap beats the Nifty 500 TRI over 90% of the time on a rolling 1-year basis over the past 4 years; on a longer 3-year return too, its outperformance over the index is strong. However, its volatility is also on the higher side and it is not the best at downside containment.

PGIM Flexicap can be used by moderate to high-risk investors as part of long-term portfolios of at least 5-7 years. It is best paired along with lower-volatile funds from this Prime Funds bucket, given its higher risk. Do not let it be the only moderate-risk fund in your portfolio.

We are removing Motilal Oswal S&P 500 from our passive segment as the fund cannot take fresh investments due to the current RBI restrictions. We will likely reinstate this fund once the limits for investments are relaxed by RBI. Until such time, continue to hold your current investments in the fund, as it provides broad based exposure to US markets.

Equity – Aggressive

In this category, we have introduced a few changes keeping in mind the need for investors to earn superior returns when they decide to take risk. It is now increasingly clear that very few funds can deliver alpha over a sustained period of time in the mid and small cap space. Besides size becoming a deterrent, slips in performance (due to few calls going wrong) also makes it hard for funds to make a quick comeback as peers overtake. 

So, some amount of churn or tactical calls to buttress your portfolio returns may become inevitable. With this in mind, we have added a couple of aggressive funds that we think would fit those who are looking at high returns with high risk. These are funds that we may decide to take out at any time if we see any warning signs of performance slackening. Please read the ‘Why this fund’ details for every fund you choose from Prime Funds, for suitability.

Besides this, we have removed an international fund that is presently barred from taking fresh money due to RBI’s restrictions on international investing. We have given an alternative for it. Now for the changes and reviews.

We have added Mahindra Manulife Midcap Unnati Yojana to our aggressive category. This midcap fund has been quite nimble, managing to deliver index beating returns over rolling 1- and 3-year periods. On a rolling 3-year return basis it beat its benchmark 100% of the time. Only one other fund in the midcap space boasts of this record. It held ground both in the March 2020 correction as well as the recent one in March 2022. However, we do think it is still yet to be sufficiently tested on the downside. 

Laden with a portfolio of stocks that are linked to economic growth, its investment style does appear cyclical. Hence, volatility should be expected. This fund is only for those who can stomach risks. A new fund house with limited track record and the possibility of losing fund managers to large AMCs remain risks. Hence, temper your exposure. Use the SIP route if you decide to invest.

We have introduced a new ‘Equity Aggressive – Tactical’ category to allow you to ride market momentum where you prefer it as a strategy. We will place funds that we identify as being great performers but those that may or may not make the cut in terms of the fundamentals we look for in a portfolio. 

In this segment, we are adding one fund - Quant Active – a multi-cap fund that churns its portfolio constantly to ensure it rides stocks that gather momentum. It appears to follow a momentum-driven strategy based on economic, sector and market conditions. Its performance and risk profile are closer to midcap funds despite being a multi-cap fund. It has managed to contain declines well in the recent correction as well.

With only a little over half a dozen funds in the multi-cap space, this fund is head and shoulders above the peers in terms of consistency in outperformance in the last 1 and 3 years. It scores well even when compared with the midcap category average. However, this pick is a clear deviation from our philosophy of picking funds with a long-term potential. In fact, we think there are stocks in the portfolio that would not make the quality cut in our filters.

We may decide to take tactical calls on exiting the fund at a later date, if warranted. This fund is suitable only for high-risk investors who can review their portfolios regularly and act on calls when we suggest. Use SIP route. Being a small AMC, its continuity under similar management will be a big risk. Exposure is best kept to 5% of your portfolio.

In our equity passive space, the Motilal Oswal Nasdaq 100 FoF has not been able to take fresh investments owing to RBI’s restrictions. We are therefore introducing Kotak Nasdaq 100 FoF as an alternative. This fund invests in iShares Nasdaq 100 UCITS ETF. Since the cap on foreign investment is not hit in this category yet (FoFs investing in foreign ETFs), this fund is still available for investments. You need not exit the Motilal Oswal Nasdaq 100 FoF. In fact, you can choose to wait for the RBI to relax the restrictions and restart investing in the Motilal Nasdaq 100 fund. We are only providing an alternative for those who wish to invest afresh.

A fund in the equity aggressive category that we wish to draw your attention to is DSP Midcap. There is no change in our call, just an update. We have been noting the underperformance of this fund and expected its portfolio changes to help it recover gradually. From an underperformance of about 20 percentage points in the last quarter (rolling 1-year return), it has narrowed to about 8 percentage points now. This is suggestive of a climb back. We will continue to watch over this improvement and are encouraged by this development.

Strategy/thematic

Our additions in this Prime Funds have been timely to capture different opportunities – in commodities, infrastructure, IT, consumption, banking. Therefore, we are not adding any funds here. However, we are consolidating this list.

One, we are removing SBI Banking & Financial Services. The fund has seen marked underperformance compared to other banking sector funds. Its concentrated portfolio is heavily dependent only on banks  - HDFC Bank and ICICI Bank in particular - with smaller exposure to other segments in the financial space. In our view, ICICI Pru Banking & Financial Services, also part of Prime Funds, is a broader play on the theme. Hold investments made in the SBI fund and do not exit.

Two, we are removing Baroda BNP Paribas India Consumption. This consumption-themed fund was wide-ranging in terms of the sectors it chose to play the consumption opportunity. However, the fund’s performance compared to other consumption funds has paled, partly due to the more large-cap, banking and staples-focused portfolio. We are also cautious due to the mergers between the Baroda and BNP Paribas fund houses. Exit investments made in this fund. The other consumption fund in our list – Nippon India Consumption Fund – has held up in performance.

Hybrid funds

Our recommendations here cover the entire range of hybrid fund categories. We have made only one addition here and one classification change.

Hybrid – Low Risk

ICICI Prudential Balanced Advantage was originally in this bucket. We had moved it to the Hybrid – High Risk segment in the September 2020 review as it turned aggressive on the unhedged equity allocation it took during the volatile period in early 2020 which upped its volatility and hurt its short-term downside containment. Over the past several months, though, the fund has been far more conservative in its allocations and volatility. Therefore, we have moved it back into the Hybrid - Low Risk segment.

Hybrid – Moderate Risk

In this bucket, we have added Edelweiss Balanced Advantage. The fund is among the most aggressive in the balanced advantage category, with unhedged equity (i.e., equity that is not covered by derivative calls) going up to 75-78% against the 43% that is the average for the category. This aggression reflects in its returns with average 1-year returns beating the category by nearly 4 percentage points; the fund is also a consistent outperformer in the category. However, it also has high volatility and poorer downside containment.

The fund is better suited to deliver debt-plus returns in portfolios rather than as a downside containment move. Investors can use it as the hybrid exposure in long-term portfolios to reduce pure equity allocation. It is avoidable for near-term goals, given its aggressive nature.

Debt Funds

The yield up-move for the 10-year G-Sec from 6.4% at the beginning of January 2022 to 6.9% has caused quite a bit of turbulence yet again in debt funds as prices of debt instruments fell to readjust to higher yields. Yield to Maturity (YTM) of debt funds have slowly but steadily been on the rise. 

Until such time the higher coupon rates from newer instruments adequately compensate for the capital loss arising from rate up-move, you will continue to find debt funds volatile and low yielding. The only way is to wait it out. We have already positioned our Prime Funds to capture the returns post this transition by adding more shorter duration options as well as select credit risk options, over the last two quarters. We have no changes in this quarter.

However, for those with income needs, we have been urging you to look at our deposit options as well as use the FD tool to pick deposits from other banks. Besides, beginning 2022, we introduced select calls on G-Secs/SDLs and private bonds for our Growth subscribers looking for more nuanced income options. Do check them.

Prime ETFs

Prime ETFs is our list of ETF recommendations in equity, debt and gold. We’re sneaking in the update to our ETF recommendations in this review report – since we’ve made only one addition 😊

Debt & Gold

In this review, we have added a debt ETF – the Bharat Bond April 2023 ETF. This is a passive debt ETF that mimics an index built with only AAA PSU bonds with underlying instrument maturity in 2023. The top-quality portfolio makes it a low-risk option and yields can be higher than similar-term bank deposits. This apart, the very short-term horizon limits market price volatility. The ETF has reasonable trading volumes and tracking error. It is a useful option to meet very short-term goals or for liquidity in ETF portfolios. It can be used along with other deposits or very short-term debt funds as well for short-term requirements.

You can find the full Prime Funds list here.

You can find the full Prime ETFs list here.

More like this

15 thoughts on “Quarterly review – changes to Prime Funds, our fund recommendations”

  1. hi Team,
    I started investing Nifty and next nifty index funds past 1 year and Low volatility fund recently. I have investments in Kotak Flexicap, Invesco contra and Motilal Oswal 35 funds around 10 Lakhs. I want to shift corpus from these non performing funds to Index funds. Please suggest the optimum way to shift. Can i change through STP or lump payments tranches.
    thanks
    Balaji

      1. hi,
        Thanks for the reply and article is good on switches. I have on going SIP’s in UTI Nifty and UTI next nifty. If I switch from above funds and with ongoing SIP’s the funds portfolio allocation will be more 25 %. Should I invest in 2 different Index funds from different AMC’s to reduce the overall percentage risk on Funds and AMC.
        thanks
        Balaji

        1. Concentration risk of AMC is less of an issue with passive funds. So not to worry. Of course, you can do so if you still feel uncomfortable. thanks. Vidya

  2. hi team,
    Can you please give your views on recently launched UTI S&P BSE Low Volatility Index Fund – Direct Plan. Please compare with ICICI Pru Low Vol ETF since both are Low Volatility and let us know if we can invest in this fund. Please provide your review on uti midcap 150 quality 50 index fund also.
    thanks
    Balaji

  3. Hello Team Primeinvestor,
    During ur quartly review dt.11/04/21, you had recommended ICICI PRUDENTIAL COMM fund
    That call has played out very well. During reco it
    was stated that “Periodic profit booking is must in such funds”. My query is how do you know the ideal time for periodic profit booking, is it after few months or atleast a year (to avoid STCG)or is it the extent of gains you have made. Should I book all the profit or at a later date since the supply chains are still disrupted due to the russia-ukrain war.
    Thanks.

    1. Hello Sir, look at the % you invested in – i.e % of your portfolio. For example, if it was 5% and has grown to 10%, bring it back to 5. if it is merely 6-7% you don’t need to. This is rebalancing based on your own portfolio rather than external events. It works well enough. Thanks, Vidya

      1. Thanks Mam for your prompt reply. Got a lot of clarity. Would like to invest in Quant Active. The proceeds are from a long time underperforming fund. Should I make a lumpsum investment or a STP.
        Thanks.

  4. t.chatterjee4u

    Thanks for keeping us posted. You guys rock! There is something I need to ask. What do you think of the popularity risk of a fund and how it could affect its performance? For instance, Parag Parikh Flexi Cap Fund has grown explosively in the past two years. Even though it’s mostly a large-cap fund, do you think the fund will be able to maintain its performance if it grows at the current rate? Also, the AUM of the SBI Small Cap Fund has gone up past the 10000 crore mark. All funds will anyway grow big with time, but for a small-cap fund, how concerning is the 10000 crore AUM? The same query goes for ICICI Prudential Balanced Advantage Fund which is about to touch 40000 crores. Thank you.

    1. Hello Sir, in the present situation size is a challenge for small cap and to some extent midcap funds and this too has to be seen in the context of the turnover (free float) of stocks in the funds. Some small cap funds with good float stocks manage quite well despite growth in AUM. The other categories’ performance has little to do with size. It is merely cyclicality of performance and at times may coincide with size.

      thanks
      Vidya

  5. Sooner than later I expect Prime Investor to cover KotakAlpha ETF although it is just 3-4 months old. It is based on Nifty Alpha 50 Index which is beating all Indices ( Nifty50, Nifty Next 50, Nifty Midcap, Nifty Smallcap, Momentum 200) in all frames.

  6. RAJENDRA PAREKH

    hdfc balanced advantage has done very well , why dont you include it in the respective category. ?

    1. Hello Sir, No. They don’t have much of a derivative strategy and are extremely volatile.The reason they have high returns is because they use less derivatives. That’s not what BAA is expected to do! 🙂 Vidya

Comments are closed.

Hold On

You are being redirected to another page,
it may take a few seconds.
Login to your account
OR

Become a PrimeInvestor!

Get stock & mutual fund recommendations

Start registration

Start registration

OR
user icon
user icon
user icon

Terms & Conditions

A copy of the T&C has been sent to your email.

Last modified on February 18, 2025

This website www.primeinvestor.in (“Website”) is owned and operated by PrimeInvestor Financial Research Pvt. Ltd. (“RA”), a SEBI-registered Research Analyst with Registration No. INH200008653.

Through the Website, the RA allows clients to access research recommendations, research reports, and model portfolios, along with tools, personal finance products, and articles, on the payment of a subscription fee (“Research Services”). The terms ‘RA’ or ‘us’ or ‘we’ refer to PrimeInvestor Financial Research Pvt Ltd (SEBI RA Registration No INH200008653) who are the owners of this Website and offering the Research Services. The term ‘you’ and ‘client’ refers to the subscriber of the Services on the Website. The RA provides the Research Services subject to the notices, terms, and conditions set forth in these Terms. By accepting these Terms when you subscribe to the Research Services, you provide your consent to abide by these Terms.

Most Important Terms and Conditions (MITC)

[Forming part of the Terms and Conditions for providing research services]

  1. These terms and conditions, and consent thereon are for the research services provided by the Research Analyst (RA) and RA cannot execute/carry out any trade (purchase/sell transaction) on behalf of the client. Thus, the clients are advised not to permit RA to execute any trade on their behalf.
  2. The fee charged by RA to the client will be subject to the maximum amount prescribed by SEBI/ Research Analyst Administration and Supervisory Body (RAASB) from time to time (applicable only for Individual and HUF Clients).
    Note:
    • SEBI's current cap on fee is Rs 1,51,000/- per annum per family of client for all research services of the RA.
    • The fee limit does not include statutory charges.
    • The fee limits do not apply to a non-individual client / accredited investor.
  3. RA may charge fees in advance if agreed by the client. Such advance shall not exceed the period stipulated by SEBI; presently it is one quarter. In case of pre-mature termination of the RA services by either the client or the RA, the client shall be entitled to seek refund of proportionate fees only for the unexpired period.
  4. Fees to RA may be paid by the client through any of the specified modes like cheque, online bank transfer, UPI, etc. Cash payment is not allowed. Optionally the client can make payments through Centralized Fee Collection Mechanism (CeFCoM) managed by BSE Limited (i.e. currently recognized RAASB).
  5. The RA is required to abide by the applicable regulations/ circulars/ directions specified by SEBI and RAASB from time to time in relation to disclosure and mitigation of any actual or potential conflict of interest. The RA will endeavor to promptly inform the client of any conflict of interest that may affect the services being rendered to the client.
  6. Any assured/guaranteed/fixed returns schemes or any other schemes of similar nature are prohibited by law. No scheme of this nature shall be offered to the client by the RA.
  7. The RA cannot guarantee returns, profits, accuracy, or risk-free investments from the use of the RA's research services. All opinions, projections, estimates of the RA are based on the analysis of available data under certain assumptions as of the date of preparation/publication of research report.
  8. Any investment made based on recommendations in research reports are subject to market risks, and recommendations do not provide any assurance of returns. There is no recourse to claim any losses incurred on the investments made based on the recommendations in the research report. Any reliance placed on the research report provided by the RA shall be as per the client's own judgement and assessment of the conclusions contained in the research report.
  9. The SEBI registration, Enlistment with RAASB, and NISM certification do not guarantee the performance of the RA or assure any returns to the client.
  10. For any grievances,
    • Step 1: the client should first contact the RA using the details on its website or following contact details:
      Customer care: [email protected]
      Grievance officer: [email protected], ATTN: Srikanth Meenakshi
      Compliance officer: [email protected], ATTN.: Bhavana Acharya
      Principal officer: [email protected], ATTN.: Vidya Bala
    • Step 2: If the resolution is unsatisfactory, the client can also lodge grievances through SEBI's SCORES platform at www.scores.sebi.gov.in
    • Step 3: The client may also consider the Online Dispute Resolution (ODR) through the Smart ODR portal at https://smartodr.in
  11. Clients are required to keep contact details, including email id and mobile number/s updated with the RA at all times.
  12. The RA shall never ask for the client’s login credentials and OTPs for the client’s Trading Account, Demat Account, and Bank Account. Never share such information with anyone including RA.

By browsing, viewing, using the Website and subscribing to the Research Services provided therein you consent to and agree to comply with these Terms and Conditions of subscription (“Terms”).

The RA reserves the right to change or modify the Website, the contents thereof and these Terms at any time. All modifications to these Terms & Conditions will be posted on the Website and will become effective immediately upon such posting. Changes once made will be communicated to the client. Continued use of the Website shall be construed as acceptance of the revisions to the Terms by conduct.

The following terms and conditions include but are not limited to minimum mandatory terms and conditions to clients as stipulated by SEBI.

1. Availing the research services

By accepting delivery of the research service, the client confirms that he/she has elected to subscribe to the research service of the RA at his/her sole discretion. The RA confirms that Research Services shall be rendered in accordance with the applicable provisions of the SEBI RA Regulations.

2. Obligations on RA

The RA shall be bound by the SEBI Act and all the applicable rules and regulations of SEBI, including the RA Regulations and relevant notifications of Government, as may be in force, from time to time.

3. Client Information and KYC

The client shall furnish all such details in full as may be required by the RA in its standard form with supporting details, if required, as may be made mandatory by Research Analyst Administration and Supervisory Body(RAASB)/SEBI from time to time. RA shall collect, store, upload and check KYC records of the clients with KYC Registration Agency (KRA) as specified by SEBI from time to time.

4. Standard Terms of Service

The consent of client shall be taken on the following understanding:

“I / We have read and understood the terms and conditions applicable to a research analyst as defined under regulation 2(1)(u) of the SEBI (Research Analyst) Regulations, 2014, including the fee structure.

I/We are subscribing to the research services for our own benefits and consumption, and any reliance placed on the research report provided by research analyst shall be as per our own judgement and assessment of the conclusions contained in the research report.

I/We understand that –

  1. Any investment made based on the recommendations in the research report are subject to market risk.
  2. Recommendations in the research report do not provide any assurance of returns.
  3. There is no recourse to claim any losses incurred on the investments made based on the recommendations in the research report.”

The declaration of the RA is as follows:

  1. We are duly registered with SEBI as an RA pursuant to the SEBI (Research Analysts) Regulations, 2014 and our registration details are: registration no SEBI INH200008653, with registration date 19th August, 2021
  2. We have the registration and qualifications required to render the services contemplated under the RA Regulations, and the same are valid and subsisting;
  3. Research analyst services provided by us do not conflict with or violate any provision of law, rule or regulation, contract, or other instrument to which it is a party or to which any of its property is or may be subject;
  4. The maximum fee that may be charged by the RA is ₹1.51 lakhs per annum per family of client. Our current fee structure, the term and duration of our subscription for our Research Services, can be viewed on our website here: https://primeinvestor.in/prime-pricing
  5. The recommendations provided by us as part of the Research Services do not provide any assurance of returns.

5. Consideration and mode of payment

The client shall duly pay to the RA the agreed fees for the services that RA renders to the client and statutory charges, as applicable. Such fees and statutory charges shall be payable through the specified manner and mode(s)/ mechanism(s).

The payment of fees shall be through a mode that shows traceability of funds. Such modes include but are not limited to credit cards/debit cards/ UPI/ net banking or any other mode specified by SEBI from time to time. However, the fees shall not be in cash.

6. Risk factors

  1. Investments are subject to market risk. Investing or trading in financial products involves risk. Past performance of the recommendation is not an indication of future returns. Past performance of the RA is not an indicator of future performance. Past performance of the security is not an indication of future returns.
  2. There are no assurances or guarantees that the objectives of any investment in financial products will be achieved.
  3. The names of financial products mentioned herein do not in any manner indicate their prospects or returns. The performance in the equity may be adversely affected by the performance of individual companies, changes in the market place and industry specific and macro-economic factors.
  4. The performance of the investments/ products recommended by the RA are subject to a wide range of risks, including but not limited to: performance of the respective companies, changes in equity and debt market conditions, micro and macro factors and forces affecting equity and debt markets, general levels of interest rates and interest rate risk, credit risk, liquidity risk, reinvestment risk, economic slowdown, volatility & illiquidity of the stocks, risks associated with trading volumes, liquidity and settlement systems in equity and debt markets and/or such other circumstance beyond the control of the RA or any of its Associates.
  5. Other risk factors include that may affect the performance of the investments/ products recommended by the RA include but are not limited to economic policies, changes of Government and its policies, acts of God, acts of war, civil disturbance, sovereign action and /or such other acts/ circumstance beyond the control of the RA or any of its Associates.
  6. The recommendations provided by the RA as part of its Research Services may not be suitable to all categories of investors.
  7. The client should read all scheme and security related documents carefully before investing.
  8. Returns and performance figures mentioned in the research report represent past performance and should not be constituted to be future returns or guaranteed returns.

7. Conflict of interest

The RA shall adhere to the applicable regulations/ circulars/directions specified by SEBI from time to time in relation to disclosure and mitigation of any actual or potential conflict of interest. Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

General disclosures: PrimeInvestor Financial Research Pvt Ltd (with brand name PrimeInvestor) is an independent research entity offering research services on personal finance products to customers. We are a SEBI registered Research Analyst (Registration: INH200008653). PrimeInvestor Financial Research Pvt. Ltd., its employees, directors or agents, do not have any material adverse disciplinary history as on the date of publication of this report.

Restrictions on trading: To ensure no conflict of interest, the RA declares as follows:

  1. Personal trading activities of the individuals employed as research analysts shall be monitored, recorded and subject to a formal approval by the directors or compliance officer of PrimeInvestor Financial Research Private Limited.
  2. Research analysts employed by PrimeInvestor Financial Research Private Limited or their associates or relatives shall not:
    • Deal/ trade in stocks recommended/ tracked by the research analyst within 30 days before and five days after the publication of a research report;
    • Deal/ trade in securities that the research analyst reviews in a manner contrary to the given recommendation;
    • Purchase or receive securities of the issuer before the issuer's initial public offering, if the issuer is principally engaged in the same types of business as companies that the research analyst follows or recommends.

Disclosures with respect to Research and Recommendations Services:

  1. The RA or its directors or any of its officer/employee does not trade in securities which are subject matter of recommendation.
  2. The RA, or any of its officers, directors, employees, or subsidiaries have not received any compensation/ benefits whether monetary or in kind, from the AMC, company, government, bank or any other product manufacturer or third party, whose products are the subject of its Research Services or investment information.
  3. The Research Analysts who have prepared the research reports that form part of the Research Services (“Research Analyst”) certify that all of the views expressed in the research report accurately reflect their views about the subject company or subject security.
  4. The RA or directors or employees or Research Analyst certify that no part of their compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.
  5. The Research Analyst has not served as director, officer or employee in the subject company, AMC or insurance company of the mutual fund or insurance policy that is the subject of this report, or company whose bonds, NCDs, fixed deposits or other savings products that is the subject of this report.
  6. The Research Analyst or their relatives do not have any known direct or indirect material conflict of interest including long/short positions in the subject company.
  7. The Research Analyst may hold investments in the stocks, mutual fund schemes, bonds, fixed deposits, insurance policies, or other products that are the subject of the recommendations provided as part of the Research Services. The Research Analyst certifies that they will not act in a manner contrary to their views on these securities except in the event of significant news or event or change in personal financial circumstances and without formal approval from the directors of PrimeInvestor Financial Research Pvt. Ltd. or the compliance officer.
  8. There are no actual or potential conflicts of interest arising from any connection to or association with any issuer of products/ securities, including any material information or facts that might compromise its objectivity or independence in the carrying on of the Research Services. Such conflict of interest shall be disclosed to the client as and when they arise.
  9. The RA or its directors or its employee or its associates have not managed or co-managed the public offering of any company. The RA or its directors or its employee or its associates have not received any compensation for investment banking or merchant banking of brokerage services from the subject company. The RA or its directors or its employee or its associates have not received any compensation for products or services other than above from the subject company. The RA or its directors or its employee or its associates have not received any compensation or other benefits from the Subject Company or 3rd party in connection with the research report/ recommendation.
  10. The subject company of its research recommendations was not a client of the RA or its directors or its employee or its associates during twelve months preceding the date of recommendation services provided.
  11. The RA or its directors or its employee or its associates has not served as an officer, director or employee of the subject company. Research Analysts has not been engaged in market making activity of the subject company.

PrimeInvestor Financial Research Pvt. Ltd., its Associates, the Research Analysts or their relatives holds ownership of 1% or more, in respect of the said issuer company(ies)? – NO

8. Termination of service and refund of fees:

The RA may terminate or suspend rendering of Research Services to the client in the following circumstances:

  1. On account of suspension/cancellation of registration of RA by SEBI. In case of suspension of certificate of registration of the RA for more than 60 (sixty) days or cancellation of the RA registration, RA shall refund the fees, on a pro rata basis for the period from the effective date of cancellation/ suspension to end of the client’s subscription period.
  2. The RA voluntarily chooses to terminate its Research Service. In the event of such termination of the Research Service, the RA shall refund the fees, on a pro rata basis for the period from the date of such termination of research service to end of the client’s subscription period.

9. Grievance redressal and dispute resolution:

Any grievance related to:

  1. nonreceipt of research report, or
  2. missing pages or inability to download the entire report, or
  3. any other deficiency in the research services provided by RA

shall be escalated promptly by the client to the person/employee designated by RA, in this behalf as under:

Name: Bhavana Acharya
Designation: Director & Compliance Officer, PrimeInvestor Financial Research Pvt Ltd
Email: [email protected]

The RA shall be responsible to resolve grievances within 7 (seven) business working days or such timelines as may be specified by SEBI under the RA Regulations.

RA shall redress grievances of the client in a timely and transparent manner. Any dispute between the RA and his client may be resolved through arbitration or through any other modes or mechanism as specified by SEBI from time to time.

If the client is not satisfied with the response of the RA, he/she can lodge his/her grievances with SEBI at scores.sebi.gov.in. Alternatively, the client may also write to any of the offices of SEBI. For any queries, feedback or assistance, please contact SEBI Office on Toll Free Helpline at 1800 22 7575 / 1800 266 7575

Details on grievances are available on the Website as follows: https://primeinvestor.in/ra-grievance/

10. Additional clauses:

Scope of the Research Service: The Research Services will be limited to providing independent research recommendation and shall not be involved in any advisory or portfolio allocation services. The Research Services are not meant to be tailor-made or customized solutions that specifically apply to each client based on his/her risk profile.

The RA never guarantees the returns on the recommendation provided. Investor shall take note that investment/trading in stocks/Index or other securities is always subject to market risk. Past performance is never a guarantee of same future results. The RA shall not be responsible for any loss to the Investors.

This service is not directed for access or use by anyone in a country, especially the USA, Canada or the European Union countries, where such use or access is unlawful or which may subject PrimeInvestor Financial Research Pvt Ltd or its affiliates to any registration or licensing requirement.

The Research Service, including recommendations, research reports, updates, and other information will be accessible through the RA’s website https://primeinvestor.in only. Such recommendations and updates will not be provided over phone calls.

Fees: Our current fee structure, the term and duration of our subscription for our Research Service, can be viewed on our website: https://primeinvestor.in/prime-pricing. Eligibility for any discounts is ascertained at the time the client subscribes. Any such discount and its tenure shall be at the discretion of the RA.

Subscription and access to content services fall under the purview of Goods and Services Tax (GST) as per the current indirect taxation policy, Government of India. Unless otherwise indicated, prices stated on our website are exclusive of applicable GST, any applicable value added tax (VAT) or other sales taxes. We are a business-to-consumer (B2C) service provider and we do not commit to provide any input tax credit on GST charged on subscription to our Research Service.

We may change the Subscription Fees and charges then in effect, or add new fees or charges which will take effect at the end of the client’s subscription period, by giving notice in advance and an opportunity to cancel renewal of the subscription.

Subscription Access & Renewal: Subscription to the Website commences immediately on the realisation of payment of the Subscription Fees. Subscriptions are set to be renewed automatically at the end of the subscription period.

Unless the client notifies us before the end of his/her subscription period, or the client cancels the auto-renewal mandate within the period specified by law, that the client does not wish to renew his/her subscription, the client’s subscription will renew for the period defined by the client’s subscription plan. We will charge the subscription using the same payment method that you previously used.

Although the client may notify to us his/her intention to his/her subscription, such notice will only take effect at the end of his/her then current subscription period, and he/she will not receive a refund other than as set out under Clause 8 in these Terms.

The client may notify us of his/her wish to cancel his/her subscription by sending an email to [email protected]. The client must provide at least 5 business days advance notice for this to be implemented.

Refunds: There can be no cancellation and refund of subscription fee paid once the subscription is active, other than as stated in Clause 8 of these Terms. If the client is entitled to a refund as specified under Clause 8 of these Terms, the RA will credit that refund to the card or other payment method used by the client to submit payment, unless it has expired - in which case the RA will contact the client to proceed with the refund. If we do issue a refund or credit due to circumstances outside the obligations specified under Clause 8, we are under no obligation to issue the same or a similar refund in the future.

General disclaimers: The recommendations made herein in the Research Services are expression of views and/or opinions and should not be deemed or construed to be advice for the purpose of purchase or sale of any security, nor a solicitation or offering on any investment/ trading opportunity on behalf of the company, AMC, insurance company, or issuer of security referred to herein.

The content and research reports generated by the RA does not constitute or is not intended to constitute an offer to buy or sell, or a solicitation to an offer to buy or sell financial products, units or securities.

The information/ opinion/ views mentioned in research reports or by the RA are not meant to serve as a professional guide to the client or recipients of this Report. The research report, recommendation, or any other content published by the RA do not assure or guarantee any minimum or fixed returns to the client or recipients of the reports/ recommendations/ content.

Use of this information is at the client’s own risk. The client must make his/ her own investment decisions based on his/her specific investment objective and financial position and using such independent advisors as he/she believes necessary. The services rendered by the RA are on a best-effort basis. All information in the content or research report of the RA is provided on an as is basis. Information is believed to be reliable but the RA does not warrant its completeness or accuracy and expressly disclaim all warranties and conditions of any kind, whether express or implied.

While due care has been taken to ensure that the disclosures, information, and opinions given are fair and reasonable, PrimeInvestor Financial Research Pvt Ltd and/or none of its officers, directors, partners, employees, agents, subsidiaries, affiliates or business associates shall be liable for any direct, indirect, special, incidental, consequential, punitive or exemplary damages, including lost profits arising in any way whatsoever from the information/ opinions/ views contained in the research report and recommendations that form part of the Research Service, and/or mails, social media or notifications issued by PrimeInvestor Financial Research Pvt Ltd or any other agency appointed/authorised by PrimeInvestor Financial Research Pvt Ltd. Returns and performance figures mentioned in the research report represent past performance and should not be constituted to be future returns or guaranteed returns.

Any agreements, transactions or other arrangements made between the client and any third party named on (or linked to from) the Website are at your own responsibility and entered into at your own risk. Any information that you receive via the Website, whether or not it is classified as “real time”, may have stopped being current by the time it reaches you. Market price information may be rounded up/down and therefore may not be entirely accurate.

The purpose of these disclosures is to provide essential information about the Research Services in a manner to assist and enable the prospective client/client in making an informed decision for engaging in Research Services before onboarding.

History, present business and background: PrimeInvestor Financial Research Private Limited is registered with SEBI as Research Analyst with registration no. INH200008653. The Research Analyst got its registration on August 19, 2021 and is engaged in offering research and recommendation services.

Disciplinary history: There are no pending material litigations or legal proceedings against the Research Analyst. As on date, no penalties / directions have been issued by SEBI under the SEBI Act or Regulations made thereunder against the Research Analyst relating to Research Analyst services.

Details of the RA's associates: No associates.

Usage of Website Content: This Website is controlled and operated by the RA. All material, including research reports, recommendations, portfolios, ratings, lists of financial products, illustrations, statements, opinions, views, photographs, products, images, artwork, designs, text, graphics, logos, button icons, images, audio and video clips and software (collectively, “Content”) are protected by copyrights, trademarks and other intellectual property rights that are owned and controlled by the RA or by other parties that have licensed their material to us.

Except where otherwise agreed in writing with the RA, material on the Website is solely for the client’s personal, non-commercial use. Except as provided below, the client must not copy, reproduce, republish, upload, post, transmit or distribute such material in any way, including by e-mail or other electronic means and whether directly or indirectly and the client must not assist any other person to do so.

Without the prior written consent of the RA, modification of the materials, use of the materials on any other web site or networked computer environment or use of the materials for any purpose other than personal, non-commercial use is a violation of the copyrights, trademarks and other proprietary rights, and is prohibited. Any use for which the client receives any remuneration, whether in money or otherwise, is a commercial use for the purposes of these Terms.

The client may occasionally distribute a copy of a research report, or a portion of the same, from the Website in non-electronic form to a few individuals without charge, provided the client includes all copyright and other proprietary rights notices in the same form in which the notices appear, original source attribution, and the phrase “Used with permission from PrimeInvestor Financial Research Pvt. Ltd.”

While the client may occasionally download and store research reports or information from the Website for his/her personal use, he/she may not otherwise provide others with access to the same. The foregoing does not apply to any sharing functionality we provide through the Website that expressly allows the client to share Content or links to Content with others. In addition, the client may not use Content he/she has downloaded for personal use to develop or operate an automated trading system or for data or text mining.

The client agrees not to rearrange or modify the Content available through the Website. The client agrees not to display, post, frame, or scrape the Content for use on another website, app, blog, product or service, except as otherwise expressly permitted by these Terms. You agree not to create any derivative work based on or containing the research products and Content. The framing or scraping of or in-line linking to the Services or any Content contained thereon and/or the use of webcrawler, spidering or other automated means to access, copy, index, process and/or store any Content made available on or through the Services other than as expressly authorized by us is prohibited.

The client further agrees to abide by exclusionary protocols (e.g., Robots.txt, Automated Content Access Protocol (ACAP), etc.) that may be used in connection with the Research Services. The client may not access parts of the Research Services to which he/she is not authorized, or attempt to circumvent any restrictions imposed on your use or access of the Services.

As a general rule, the client may not use the Content, including without limitation, any Content made available through one of our RSS Feeds, in any commercial product or service, without our express written consent.

The client may not create apps, extensions, or other products and services that use our Content without our permission. The client may not aggregate or otherwise use our Content in a manner that could reasonably serve as a substitute for a subscription to the Website.

The client may not access or view the Services with the use of any scripts, extensions, or programs that alter the way the Services are displayed, rendered, or transmitted to you without our written consent.

The client agrees not to use the Services for any unlawful purpose. We reserve the right to terminate or restrict the client's access to the Website if, in our opinion, the client's use of the Services may violate any laws, regulations or rulings, infringe upon another person's rights or violate these Terms.

Prohibited content: The Website includes comments sections, blogs and other interactive features that allow interaction among clients and between clients and the RA. We call the information posted by or contributed by users “Contributed Content.” In the course of availing of the Research Services or uploading any post or comment on the Website, the client shall not post any Contributed Content that (i) contains nude, semi-nude, sexually suggestive photos, (ii) tends or is likely to abuse, harass, threaten, impersonate or intimidate other users of the Website and/or Research Services, (iii) is lascivious or appeals to the prurient interest or if its effect is such as to tend to deprave and corrupt persons who are likely to use or have access to the Website and/or Services, or (iv) otherwise violates, is prohibited or restricted by applicable law, rule or regulation, is offensive or illegal or violates the rights of, harms or threatens the safety of other users of the Website and/or Services (collectively “Prohibited Content”).

We reserve the right to cease to provide the client with the Research Services or access to the Website, or terminate your subscription, with immediate effect and without notice and liability, for violating these Terms, applicable law, rules or regulations and reserves the right to remove Prohibited Content which is in violation of these Terms, or is otherwise abusive, illegal or disruptive. The determination of whether any content constitutes Prohibited Content, violates these Terms, or is otherwise abusive illegal or disruptive, is subject to the sole determination of the Firm.

Changes to Research Services: We are constantly endeavouring to improve the quality of Research Services provided to our clients. Due to this, the form and nature of the Research Services provided may change from time to time without any prior notice to the client. We reserve the right to introduce and initiate new features, functionalities, components to the Website and/or Research Services and/or change, alter, modify, or discontinue existing ones without any prior notice to the client.

Warranty and liability disclaimer: The Website, Research Services, and all the materials and services, included on or otherwise made available to the client through this Website is provided by the RA on an “as is” and “as available” basis without any representation or warranties, express or implied except otherwise specified in writing. Without prejudice to the foregoing paragraph, the RA does not warrant that:

  • This Website and/or Research Services will be constantly available, or available at all;
  • The information on this Website or provided through the Research Services is complete, true, accurate or not misleading; or
  • The quality of any products, services, information, or other material that you obtain through the Website or Services will meet your expectations.

The RA, to the fullest extent permitted by law, disclaims all warranties, whether express or implied, including the warranty of merchantability, fitness for particular purpose and non-infringement. The RA makes no warranties about the accuracy, reliability, completeness, or timeliness of the Website, Research Services, Content, Contributed Content, Services, software, text, graphics and links.

The RA does not warrant that this Website, Research Services, information, content, materials, or any other material included on or otherwise made available to you through this Website, their servers, or electronic communication sent by the RA are free of viruses or other harmful components.

Nothing on this Website constitutes, or is meant to constitute, advice of any kind.

Indemnification: The client:

  1. Represents, warrants and covenants that no materials of any kind provided by him/her will:
    1. Violate, plagiarise, or infringe upon the rights of any third party, including copyright, trademark, privacy or other personal or proprietary rights; or
    2. Contain libellous, Prohibited Content or other unlawful material;
  2. Hereby agree to indemnify, defend and hold harmless the RA and all of the RA’s officers, directors, owners, agents, customers/clients, information providers, affiliates, licensors and licensees (collectively, the “Indemnified Parties”) from and against any and all liability and costs, including, without limitation, reasonable advocate’s fees, incurred by the Indemnified Parties in connection with any claim arising out of any breach by the client of these Terms or the foregoing representations, warranties and covenants. The client shall cooperate as fully as reasonably required in the defence of any such claim. The RA reserves the right, at its own expense, to assume the exclusive defence and control of any matter subject to indemnification by the client.

Applicable law: This Website, including the Content and Contributed Content and information contained herein, and the provision of Research Services shall be governed by the Securities and Exchange Board of India, laws of the Republic of India and the courts of Chennai, India which shall retain exclusive jurisdiction to entertain any proceedings in relation to any disputes arising out of the same. As such, the laws of India shall govern any transaction completed using this Website.

Information gathered and tracked: Information submitted or collected on the Website or pursuant to the use of the Services is stored in a database. Specifically, we store the username, name, e-mail address, contact number, as submitted or collected on our Website or through the provision of the Research Services. We may use such information to send out occasional promotional materials, including alerts on new Services available, or other promotional and marketing material relating to our clients and customers.

In accordance with the Information Technology Act 2000, the name and the details of the Grievance Officer at PrimeInvestor is provided below:

Mr. Srikanth Meenakshi
PrimeInvestor Financial Research Pvt. Ltd., Registered office: 659, 4th Avenue, D-Sector, Anna Nagar Western Extension, Chennai 600 101.
Email: [email protected]

11. Mandatory notice:

Clients shall be requested to go through Do’s and Don’ts while dealing with RA as specified in SEBI master circular no. SEBI/HO/MIRSD-POD-1/P/CIR/2024/49 dated May 21, 2024 or as may be specified by SEBI from time to time.

12. Optional Centralised Fee Collection Mechanism:

SEBI has operationalized a centralized fee collection mechanism for IA and RA. Under this mechanism, clients shall pay fees to IAs/RAs through a designated platform/portal administered by a recognized Administration and Supervision body. This is an optional mechanism for the registered entities. At this time, PrimeInvestor has opted out of this fee collection mechanism. Therefore, all subscription payments for the Research Services will be through the modes as specified in Clause 5 of these Terms.

Enter the OTP sent to (Edit)
By doing this you agree to our terms & conditions
Didn't receive OTP? Resend

Have an account?
Login To Your Account
OR
Don’t have an account ? Register for free